EDGE
Get a demo
Log In
All Updates

All Updates

icon
Filter
Partnerships
BAMF Health partners with Calyx/Invicro to accelerate radioligand and immuno-oncology therapy development
Precision Medicine
Jun 7, 2024
This week:
Product updates
Stability AI launches Stable Diffusion 3 Medium, a text-to-image model
Foundation Models
Yesterday
Product updates
Microsoft discontinues GPT Builder in Copilot
Generative AI Applications
Yesterday
Funding
BlinqIO raises USD 5 million in funding to expand operations
Generative AI Applications
Yesterday
Product updates
Databricks launches innovations to Mosaic AI for production-quality applications
Generative AI Infrastructure
Yesterday
M&A
Rebellions and Sapeon Korea merge to challenge global AI chip leader
Generative AI Infrastructure
Yesterday
M&A
Pluxee to acquire Cobee; expands employee benefits offering
Remote Work Infrastructure
Yesterday
Product updates
Space and Time launches 'Proof of SQL' solution on GitHub
Enterprise Blockchain Solutions
Yesterday
Partnerships
Lido partners with Mellow Finance to launch liquid restaking vaults
Decentralized Finance (DeFi)
Yesterday
Funding
Rivia raises EUR 3 million in seed funding
Clinical Trial Technology
Yesterday
Product updates
Partnerships
Databricks and Shutterstock collaborate to launch enterprise-optimized ImageAI model
Generative AI Infrastructure
Yesterday
Precision Medicine

Precision Medicine

Jun 7, 2024

BAMF Health partners with Calyx/Invicro to accelerate radioligand and immuno-oncology therapy development

Partnerships

  • BAMF Health and Calyx/Invicro have entered a strategic partnership to address the drawbacks of fragmented service ecosystems, which cause redundant efforts, slow knowledge transfer, and longer development times. The partnership aims to accelerate the clinical translation of radioligand therapies (RLT) and immuno-oncology (IO) agents.

  • By merging Calyx/Invicro's radiochemistry and imaging biomarker solutions with BAMF Health's radiopharmacy facility, the companies aim to solve duplicative efforts and lengthy development processes. This will provide a complete resource to translate advanced programs into clinical trials efficiently. A key venture driving this partnership is an actinium-225 project, which includes the study and application of actinium-225 in RLT, leveraging its GE HealthCare StarGuide SPECT/CT and dosimetry expertise.

  • BAMF Health specializes in advanced molecular imaging and targeted therapy, utilizing state-of-the-art AI-enabled technology to diagnose and treat diseases like cancer, Alzheimer's, and cardiovascular conditions. The company uses theranostics, which combines diagnostic imaging with targeted therapy to provide highly personalized and effective treatments​. Its key offerings include United Imaging uEXPLORER total-body PET/CT, a high-resolution scanner claimed to provide a full-body scan in five minutes.

  • Analyst QuickTake: In March 2024 , Calyx and Invicro agreed to combine the companies through an acquisition, where Calyx would obtain complete ownership of Invicro from the previous owner, REALM IDx.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.